-
Je něco špatně v tomto záznamu ?
Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry
M. Kojanova, B. Turkova, S. Gkalpakiotis, P. Cetkovska, J. Fialova, T. Dolezal, A. Machovcova, ED. Apol, BIOREP Study Group
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, pozorovací studie, multicentrická studie
- MeSH
- dermatologické látky terapeutické užití MeSH
- dospělí MeSH
- humanizované monoklonální protilátky * terapeutické užití MeSH
- kvalita života * MeSH
- lidé středního věku MeSH
- lidé MeSH
- psoriáza * farmakoterapie MeSH
- registrace * MeSH
- senioři MeSH
- stupeň závažnosti nemoci * MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- pozorovací studie MeSH
- Geografické názvy
- Česká republika MeSH
INTRODUCTION: The aim of this observational, multicenter study was to assess the real-world use of brodalumab for the treatment of moderate-to-severe plaque psoriasis in patients in the Czech Republic, using data from the BIOREP registry. METHODS: The study included 273 patients aged ≥ 18 years with moderate-to-severe psoriasis who received brodalumab. Endpoints were drug survival (time from treatment initiation to discontinuation), effectiveness [Psoriasis Area and Severity Index (PASI)], and health-related quality-of-life [Dermatology Life Quality Index (DLQI)]. RESULTS: Predicted drug survival probability was 92.4% [95% confidence interval (CI): 89.1, 95.7%] at 6 months and 84.2% (95% CI 79.5, 89.1%) at 12 months; this was maintained at 24 months [80.4% (95% CI 74.5, 86.8%)]. Younger age, higher body mass index, and no previous biologic treatment were significantly associated with longer drug survival. Absolute PASI ≤ 3 after 3 months was achieved by 89.8% of patients; 92.4%, 77.8%, and 59.1% reached PASI 75, PASI 90, and PASI 100, respectively. After 12 months, 96.5% of 141 patients had an absolute PASI ≤ 3. The proportion of patients achieving DLQI 0/1 was 87.3% at 12 months. CONCLUSION: This study demonstrated high and sustained drug survival with high rates of skin clearance and improved quality of life in patients with relatively severe disease treated with brodalumab. Improvements were observed as early as 3 months post-treatment initiation and were sustained for up to 24 months in a real-life setting.
Department of Dermatovenereology University Hospital Motol Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24018746
- 003
- CZ-PrNML
- 005
- 20241024111333.0
- 007
- ta
- 008
- 241015s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12325-024-02952-4 $2 doi
- 035 __
- $a (PubMed)39207667
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kojanova, Martina $u Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. martina.kojanova@vfn.cz
- 245 10
- $a Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry / $c M. Kojanova, B. Turkova, S. Gkalpakiotis, P. Cetkovska, J. Fialova, T. Dolezal, A. Machovcova, ED. Apol, BIOREP Study Group
- 520 9_
- $a INTRODUCTION: The aim of this observational, multicenter study was to assess the real-world use of brodalumab for the treatment of moderate-to-severe plaque psoriasis in patients in the Czech Republic, using data from the BIOREP registry. METHODS: The study included 273 patients aged ≥ 18 years with moderate-to-severe psoriasis who received brodalumab. Endpoints were drug survival (time from treatment initiation to discontinuation), effectiveness [Psoriasis Area and Severity Index (PASI)], and health-related quality-of-life [Dermatology Life Quality Index (DLQI)]. RESULTS: Predicted drug survival probability was 92.4% [95% confidence interval (CI): 89.1, 95.7%] at 6 months and 84.2% (95% CI 79.5, 89.1%) at 12 months; this was maintained at 24 months [80.4% (95% CI 74.5, 86.8%)]. Younger age, higher body mass index, and no previous biologic treatment were significantly associated with longer drug survival. Absolute PASI ≤ 3 after 3 months was achieved by 89.8% of patients; 92.4%, 77.8%, and 59.1% reached PASI 75, PASI 90, and PASI 100, respectively. After 12 months, 96.5% of 141 patients had an absolute PASI ≤ 3. The proportion of patients achieving DLQI 0/1 was 87.3% at 12 months. CONCLUSION: This study demonstrated high and sustained drug survival with high rates of skin clearance and improved quality of life in patients with relatively severe disease treated with brodalumab. Improvements were observed as early as 3 months post-treatment initiation and were sustained for up to 24 months in a real-life setting.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a psoriáza $x farmakoterapie $7 D011565
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a kvalita života $7 D011788
- 650 12
- $a stupeň závažnosti nemoci $7 D012720
- 650 12
- $a registrace $7 D012042
- 650 12
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a dermatologické látky $x terapeutické užití $7 D003879
- 651 _2
- $a Česká republika $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Turkova, Barbora $u Value Outcomes, Prague, Czech Republic
- 700 1_
- $a Gkalpakiotis, Spyridon $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Cetkovska, Petra $u Department of Dermatovenereology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic
- 700 1_
- $a Fialova, Jorga $u Department of Dermatovenereology, First Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic
- 700 1_
- $a Dolezal, Tomas $u Value Outcomes, Prague, Czech Republic
- 700 1_
- $a Machovcova, Alena $u Department of Dermatovenereology, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Apol, Eydna Didriksen $u LEO Pharma A/S, Ballerup, Denmark
- 710 2_
- $a BIOREP Study Group
- 773 0_
- $w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 41, č. 10 (2024), s. 3951-3971
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39207667 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20241015 $b ABA008
- 991 __
- $a 20241024111327 $b ABA008
- 999 __
- $a ok $b bmc $g 2201548 $s 1230719
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 41 $c 10 $d 3951-3971 $e 20240829 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
- LZP __
- $a Pubmed-20241015
